FDA Advisory Panel Votes to Loosen Rules on BPC-157, TB-500, and MOTS-C Despite Agency Scientists' Opposition An FDA advisory committee voted narrowly on July 23, 2026, to recommend that compounding pharmacies gain access to several popular peptide compounds, including BPC-157, KPV, TB-500, and MOTS-C, overriding explicit objections from the FDA's own career scientists and sparking an audible gasp in the meeting room when the tally was announced
We understand that life can get busy, and sometimes self-care takes a backseat
Chronically taking 7.5 mg when you think you are taking 5 mg means you are on a different pharmacological trajectory than intended
Once cagrilintide is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution
PCAC review pending)
Pediatric obesity is common, but safety and efficacy data for tirzepatide in children and adolescents are limited